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The in vitro sensitivity of Plasmodium falciparum isolates to chloroquine and amodiaquine were 
assessed in children with symptomatic uncomplicated malaria in Ibadan, Nigeria. The WHO standard in 
vitro micro-test method was employed for the study. A total of one hundred and two children were 
admitted into the study. Inhibition of schizont maturation at varying concentration of the study drugs 
was used as an index for drug activity. Effective concentrations by probit analysis of log dose/response 
for 50, 90 and 99% (EC50, EC90and EC99) inhibition were 0.37, 2.38 and 5.76 mol/l, respectively, for 
chloroquine and 0.06, 0.26 and 0.59 mol/l, respectively, for amodiaquine. Forty isolates of P. 
falciparum were tested for chloroquine sensitivity. Eighty percent (32/40) showed schizont maturation 
at 1.6 mol/l and were classified as resistant, while 39% (14/36) of isolates tested for amodiaquine 
matured at 0.4 mol/l and were also classified as resistant. This shows that amodiaquine is significantly 
more effective than chloroquine. While this data provides no absolute demonstration of chloroquine 
resistance, it underlies the need for continuous monitoring of the susceptibility of P. falciparum to 
chloroquine in southwest Nigeria. 
  





Malaria is one of the most common causes of childhood 
morbidity and mortality in sub-Saharan Africa. Every 
year, an estimated 1.5-2.8 million people, mostly children, 
die from Plasmodium falciparum malaria (WHO, 1996). 
The situation is further worsened by the widespread and 
increasing resistance of P. falciparum to chloroquine 
(CQ), the drug that has been the mainstay of malaria 
treatment for decades (White et al., 1992). Despite the 
spread of resistance, most African countries continue to 
use chloroquine as the first-line drug for uncomplicated 
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relatively affordable, readily available and relatively safe 
(Sowunmi et al., 1997). Amodiaquine (AQ), a 4-
aminoquinoline antimalarial drug similar to CQ is one of 
the few possible alternatives to chloroquine and it has 
been shown to be effective and affordable (Brasseur et 
al., 1999). Although global use of amodiaquine has 
declined owing to reports of its potential toxicity 
especially when used prophylactically (Phillips-Howard et 
al., 1990; WHO, 1990a), evidence are accumulating that 
supports its use in the treatment of uncomplicated 
malaria (Olliaro et al., 1996; Staedke et al., 2001) with the 
provision that monitoring of efficacy and toxicity should 
continue. In this study, the susceptibility of P. falciparum 
parasites to chloroquine and amodiaquine were 
evaluated and compared in an in vitro assay in order to 
determine the current level of efficacy of these drugs in 
the  treatment  of   uncomplicated  malaria   in  southwest 







MATERIALS AND METHODS 
 
Study site and patients 
 
The study was conducted in Ibadan, south-western Nigeria, where 
P. falciparum is the predominant species causing majority of 
infection (Salako et al., 1990). One hundred and two children were 
admitted into the study between April and August 2003, at the 
Children Out Patient Clinic (CHOP) of the University College 
Hospital Ibadan. Children who were enrolled into the study proper 
satisfied the following criteria: history of fever in the 24 h preceding 
presentation or pyrexia at presentation (>37.5°C), pure P. 
falciparum asexual parasitaemia >1,000/µL of blood, no antimalarial 
drug administration in the two weeks preceding presentation and 
negative urine tests (Dill-Glazko and Lignin) for antimalarial drugs. 
Informed  (written/verbal) consent of parent or guardian of each 




Collection of P. falciparum isolates 
 
1 ml of blood was collected from each child by venepuncture into 
sterile EDTA tube. Thick and thin blood films were made from the 
sample for parasitological examinations and were stained with 4% 
Giemsa’s stain for 20 min. Parasitaemia was quantified per 200 
white blood cells on a thick film and expressed as parasites/µL. A 
slide was considered negative if examination of at least 200 oil 
immersion fields revealed no parasites. 
 
 
In vitro drug sensitivity assay 
 
Thick and thin blood films were prepared from the blood collected 
from each subject for parasite identification. Two antimalarial drugs 
chloroquine (CQ) and amodiaquine (AQ) were used in this assay. 
Microtitre plates were pre-dosed with 50 µL of varying 
concentrations of the drugs. Dosing started with the control well (A) 
and followed an increasing order of drug concentration ending at 
well H (the highest concentration). For chloroquine, A=0, B=0.1, 
C=0.2, D=0.4, E=0.8, F=1.6, G=3.2 and H=6.4 µmol/L. For 
amodiaquine, A=0, B=0.025, C=0.05, D=0.1, E=0.2, F=0.4, G=0.8 
and H=1.6 µmol/L. According to WHO standard methods and 
concentrations (WHO, 1990b), 900 µL of culture medium (RPMI 
1640) was added to 100 µL of blood from each patient in a blood 
medium  mixture of ratio 1:9. All the wells of the appropriate column 
were dosed with 50 µL of the blood-medium mixture. Dosing started 
with the control well (A) and followed an increasing order of drug 
concentration ending at well H. The patient’s name, the date, the 
type of drug and the hour of incubation was inscribed on the plate. 
The pre-dosed microtitre plates were placed into a candle jar 
(vacuum desiccator) containing a candle. The candle was lit and 
the lid of the jar was replaced just before the candle flame went out 
(giving an atmosphere of relatively high CO2 and low O2 content). 
The jar was then incubated at 37°C (±0.5°C) for 24-36 h following 
the Jensen and Trager method (Jensen et al., 1977; Noedl et al., 
2003). After incubation, the supernatant from each microtitre plate 
was discarded. A thick blood film was made from the sediment at 
Ihe bottom of each well on a column, on the same microscope slide 
for each patient and labeled accordingly. The slides were then 
airdried stained for 20 min and examined by light microscopy. The 
blood film was examined under x100 oil immersion objective. The 





used to assess schizont maturation inhibition. Cultures with less 
than 10 schizonts per 200 trophozoites were excluded from the 
analysis. The test was considered valid if 10% of the parasites in 
the control well had reached schizont stage within 24-36 h. The 
IC50, IC90 and IC99 concentrations producing 50, 90 and 99% 
inhibition were taken as the measure of the response of the 
biological systems of the parasite to drugs. Parasite isolates were 
then classified as sensitive or resistant to a particular drug 
according to the drug concentration at which schizont maturation 
was completely inhibited. The degree of resistance of P. falciparum 





Drug concentrations inhibiting parasite growth were calculated 
using the probit regression analysis based on the SPSS software 
package (Wernsdorfer et al., 1995). Data not conforming to normal 
distributions were log-transformed. 
 
 
RESULTS AND DISCUSSION 
 
A total of 102 children were screened for this study. Out 
of these subjects, only 62 fulfilled the criteria for 
enrollment. The characteristics of these subjects are 
shown in Table 1. Sixty two isolates of P. falciparum were 
collected from these subjects for the in vitro drug 
sensitivity assay. The proportions of valid tests were 
40/62 for chloroquine and 36/62 for amodiaquine. Other 
tests were discarded due to lack of satisfactory schizont 
growth. 
The mean IC50, IC90 and IC99 for chloroquine and 
amodiaquine, derived using the probit regression analysis 
are shown in Table 2. This result shows decreased 
susceptibility of P. falciparum isolates to chloroquine 
compared with amodiaquine. Both drugs however, did not 
show satisfactory response as growth was observed 
above the WHO discriminating concentration for 
satisfactory response which is complete schizont 
inhibition at  0.4 µmol/L for chloroquine and at  0.2 
µmol/L for amodiaquine (WHO, 1987). 95% (38/40) of the 
isolates tested for chloroquine sensitivity matured at 0.8 
µmol/L while 39% (14/36) of the isolates tested for 
amodiaquine sensitivity matured at 0.4 µmol/L, which 
indicated resistance to these drugs (WHO, 1987). 
Chloroquine drug pressure remains high in Nigeria, as 
it is still the first-line drug in malaria therapy both as self 
treatment at home and in health care facilities. The spate 
of chloroquine resistance has therefore necessitated the 
evaluation of an alternative antimalarial drug that is 
effective, safe and affordable. Data from our in vitro study 
shows that amodiaquine is more potent blood 
schizonticide than chloroquine. The minimum drug 
concentration causing 90% inhibition of schizont 
maturation shows considerable higher activity of 
amodiaquine (0.26 µmol/l) when compared with 
chloroquine (2.38 µmol/l) against sensitive strains of P. 
falciparum. This data lends support to earlier  clinical  trial  




                                                      Table 1. Characteristics of subjects who satisfied the inclusion criteria. 
 
Subjects’ parameters Values 
Number of subjects 62 
Mean age (months) 28.5 (±17.1)a 
Mean weight (Kg) 11.4 (±3.1)a 
Mean packed cell volume (PCV) 25.5 (±5.4)a 
Percentage male 63 (39/62) 
Geometric mean parasite density (per l) 14,674 (468 - 69,474)b 
 
                                                                                           aStandard deviation in parentheses.  
                                                                                             bRange in parenthesis. 
                                                 
 







                         
                  
 
which also found amodiaquine to be more effective than 
chloroquine for the treatment of uncomplicated falciparum 
malaria (Brasseur et al., 1999; WHO, 1987; Sowunmi et 
al., 2001). This data therefore suggests that amodiaquine 
should be investigated more for treatment of chloroquine-
resistant P. falciparum malaria in Nigeria. At least 80% 
(32/40) of the isolates tested in the chloroquine group, 
matured at a concentration above 0.8 µmol/l, which 
indicate a high level of resistance to the drug. These 
results also confirm earlier reports that chloroquine 
resistance is increasing in south-west Nigeria (Spencer et 
al., 1983; Sowunmi et al., 1997; Salako et al., 1987). 
However, there seems to be a gradual build up of 
resistance to amodiaquine as 39% of the isolates tested 
grew at amodiaquine concentration of 0.4 µmol/l. Such 
was also observed in a clinical study where resistance 
was noted in some isolates from subjects in Senegal 
(Brasseur et al., 1999). Cross-resistance to chloroquine 
and amodiaquine may rise, since both drugs belong to 
the same amino-quinoline family. Hence, caution should 
be exercised with the introduction of amodiaquine as 
monotherapy for uncomplicated malaria. Studies are 
underway to assess the potential clinical value of 
combining amodiaquine with other drugs to delay the 
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